Immunic Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Selling, General & Admin	18.01	16.01	15.26	13.3	10.33	Upgrade
Research & Development	80.05	83.22	71.26	61.12	38.64	Upgrade
Operating Expenses	98.05	99.22	86.52	74.42	48.97	Upgrade
Operating Income	-98.05	-99.22	-86.52	-74.42	-48.97	Upgrade
Interest & Investment Income	3.39	3.08	1.04	0.07	0.06	Upgrade
Currency Exchange Gain (Loss)	-	-	-	-	2.5	Upgrade
Other Non Operating Income (Expenses)	-1.05	2.54	-1.96	-1.35	2.4	Upgrade
EBT Excluding Unusual Items	-95.71	-93.61	-87.44	-75.7	-44.02	Upgrade
Impairment of Goodwill	-	-	-32.97	-	-	Upgrade
Asset Writedown	-4.8	-	-	-	-	Upgrade
Other Unusual Items	-	-	-	-17.25	-	Upgrade
Pretax Income	-100.51	-93.61	-120.41	-92.95	-44.02	Upgrade
Net Income	-100.51	-93.61	-120.41	-92.95	-44.02	Upgrade
Net Income to Common	-100.51	-93.61	-120.41	-92.95	-44.02	Upgrade
Shares Outstanding (Basic)	100	44	32	24	16	Upgrade
Shares Outstanding (Diluted)	100	44	32	24	16	Upgrade
Shares Change (YoY)	126.03%	39.29%	34.52%	51.00%	102.84%	Upgrade
EPS (Basic)	-1.00	-2.11	-3.78	-3.93	-2.81	Upgrade
EPS (Diluted)	-1.00	-2.11	-3.78	-3.93	-2.81	Upgrade
Free Cash Flow	-85.03	-71.16	-65.26	-83.3	-46.27	Upgrade
Free Cash Flow Per Share	-0.85	-1.61	-2.05	-3.52	-2.95	Upgrade
EBITDA	-97.92	-99.11	-86.44	-74.33	-48.93	Upgrade
D&A For EBITDA	0.13	0.11	0.08	0.09	0.04	Upgrade
EBIT	-98.05	-99.22	-86.52	-74.42	-48.97	Upgrade

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q